Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again

Phase 3positiveivonescimabKeytrudaPositive

AI Analysis

Summary

Summit Therapeutics and Akeso's PD-1/VEGF combination therapy ivonescimab demonstrated improved overall survival compared to Merck's Keytruda in a Phase 3 trial in Chinese lung cancer patients, though results require confirmation in non-Chinese populations.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

ivonescimab improved overall survival compared to Keytruda in Chinese lung cancer patients

Importance:7/10

Sentiment:

0.75

oncologylung cancerimmunotherapyPhase 3ChinaPD-1/VEGF

Related Companies

$MRK $CHHE

Read the original article

Published by BioSpace on September 3, 2026 1:26 PM

Read Original